Literature DB >> 15121171

Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer.

Armin Blesch1.   

Abstract

Retroviral vectors have become an important tool for gene transfer in vitro and in vivo. Classical Moloney murine leukemia virus (MLV) based retroviral vectors have been used for over 20 years to transfer genes into dividing cells. Cell lines for production of retroviral vectors have become commonly available and modifications in retroviral vector design and use of envelope proteins have made the production of high titer, helper-free, infectious virus stocks relatively easy. More recently, lentiviral vectors, another class of retroviruses, have been modified for in vitro and in vivo gene transfer. The ability of lentiviral vectors to transduce non-dividing cells has made them especially attractive for in vivo gene transfer into differentiated, non-dividing tissues. Several improvements in helper plasmids and vectors have made lentivirus a safe vector system for ex vivo and in vivo gene transfer. This review will briefly summarize the background of these vector systems and provide some common protocols available for the preparation of MLV based retroviral vectors and HIV-1 based lentiviral vectors. Copyright 2003 Elsevier Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15121171     DOI: 10.1016/j.ymeth.2003.11.005

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  33 in total

1.  Vector-based RNA interference of cathepsin B1 in Schistosoma mansoni.

Authors:  Elissaveta B Tchoubrieva; Poh C Ong; Robert N Pike; Paul J Brindley; Bernd H Kalinna
Journal:  Cell Mol Life Sci       Date:  2010-03-26       Impact factor: 9.261

Review 2.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 3.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

4.  Effects of retrograde gene transfer of brain-derived neurotrophic factor in the rostral spinal cord of a compression model in rat.

Authors:  Tengfei Zhao; Yan Li; Xuesong Dai; Junbo Wang; Yiying Qi; Jianwei Wang; Kan Xu
Journal:  Mol Biol Rep       Date:  2012-04-25       Impact factor: 2.316

5.  Advances in homology directed genetic engineering of human pluripotent and adult stem cells.

Authors:  Kalpith Ramamoorthi; Donald Curtis; Prashanth Asuri
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

6.  GENE THERAPY FOR THE TREATMENT OF PITUITARY TUMORS.

Authors:  Silvia S Rodriguez; Maria G Castro; Oscar A Brown; Rodolfo G Goya; Gloria M Console
Journal:  Expert Rev Endocrinol Metab       Date:  2009-07-01

7.  Either brain-derived neurotrophic factor or neurotrophin-3 only neurotrophin-producing grafts promote locomotor recovery in untrained spinalized cats.

Authors:  Karen Ollivier-Lanvin; Itzhak Fischer; Veronica Tom; John D Houlé; Michel A Lemay
Journal:  Neurorehabil Neural Repair       Date:  2014-05-06       Impact factor: 3.919

8.  Axonal transport of neural membrane protein 35 mRNA increases axon growth.

Authors:  Tanuja T Merianda; Deepika Vuppalanchi; Soonmoon Yoo; Armin Blesch; Jeffery L Twiss
Journal:  J Cell Sci       Date:  2012-10-24       Impact factor: 5.285

9.  Promoting directional axon growth from neural progenitors grafted into the injured spinal cord.

Authors:  Joseph F Bonner; Armin Blesch; Birgit Neuhuber; Itzhak Fischer
Journal:  J Neurosci Res       Date:  2010-05-01       Impact factor: 4.164

10.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).

Authors:  Joanna L Howarth; Youn Bok Lee; James B Uney
Journal:  Cell Biol Toxicol       Date:  2009-10-15       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.